申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
公开号:US09371320B2
公开(公告)日:2016-06-21
The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof.
The present invention relates to a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
本发明提供了一种具有优异的JAK抑制作用的化合物,可用作自身免疫性疾病(类风湿性关节炎、牛皮癣、炎症性肠病、Sjogren综合症、Behcet病、多发性硬化症、系统性红斑狼疮等)、癌症(白血病、子宫平滑肌肉肉瘤、前列腺癌、多发性骨髓瘤、消耗症、骨髓纤维化等)等的预防或治疗剂,或其盐。本发明涉及一种由式中各符号如规范中所定义的化合物,或其盐。